Residency · Residency · Medical Genetics Genomics
Pharmacogenomics Fundamentals: CYP450 Enzymes and Drug Metabolism
Introduction
Pharmacogenomics (PGx) studies how genetic variation influences drug response, including efficacy, dosing, and adverse reactions. The cytochrome P450 (CYP450) superfamily of enzymes is central to Phase I drug metabolism, and genetic polymorphisms in these enzymes account for a substantial proportion of interindividual variability in drug response.
Pharmacokinetics and Drug Metabolism Overview
Phases of Drug Metabolism
Phase I (functionalization) involves oxidation, reduction, and hydrolysis reactions primarily mediated by CYP450 enzymes, introducing or exposing a functional group. Phase II (conjugation) includes glucuronidation (UGTs), acetylation (NATs), sulfation, methylation, and glutathione conjugation, increasing water solubility for excretion. Phase III (transport) involves efflux and uptake transporters (P-glycoprotein/ABCB1, OATPs, OCTs) that determine drug distribution and elimination.
Key CYP450 Enzymes in Clinical Practice
CYP2D6 metabolizes approximately 25% of clinically used drugs, including opioids (codeine, tramadol), antidepressants (SSRIs, TCAs), tamoxifen, and beta-blockers. CYP2C19 metabolizes proton pump inhibitors, clopidogrel (prodrug activation), voriconazole, and some antidepressants and antiepileptics. CYP2C9 metabolizes warfarin, phenytoin, NSAIDs, and sulfonylureas. CYP3A4/5 makes the largest contribution to drug metabolism (approximately 50% of drugs), handling statins, calcineurin inhibitors, and many chemotherapeutics, though it has less clinically actionable PGx variation compared to CYP2D6, CYP2C19, and CYP2C9. CYP1A2 metabolizes caffeine, theophylline, and clozapine and is influenced by smoking and dietary factors.
Pharmacogenomic Phenotypes
Metabolizer Categories
Ultrarapid metabolizers (UM) have increased enzyme activity due to gene duplications or gain-of-function variants and may experience therapeutic failure of active drugs or toxicity from prodrugs. Normal (extensive) metabolizers (NM/EM) have typical enzyme activity with standard dosing applicable. Intermediate metabolizers (IM) have reduced enzyme activity and may require dose adjustments. Poor metabolizers (PM) have absent or severely reduced enzyme activity with the highest risk for adverse effects from active drugs or therapeutic failure from prodrugs.
Activity Score System
CPIC (Clinical Pharmacogenetics Implementation Consortium) uses an activity score (AS) system for CYP2D6 and CYP2C19. Each allele is assigned a value (0, 0.5, or 1), and the sum determines the diplotype activity score. For CYP2D6, an AS of 0 indicates PM status, 0.25-1 indicates IM, 1.25-2.25 indicates NM, and greater than 2.25 indicates UM.
| Metabolizer Phenotype | Activity Score (CYP2D6) | Enzyme Activity | Effect on Active Drugs | Effect on Prodrugs | Clinical Action |
|---|---|---|---|---|---|
| Ultrarapid (UM) | >2.25 | Increased | Therapeutic failure (rapid clearance) | Toxicity (excess active metabolite) | Avoid prodrug or use alternative |
| Normal (NM) | 1.25–2.25 | Typical | Standard response | Standard response | Standard dosing |
| Intermediate (IM) | 0.25–1 | Reduced | Increased exposure/toxicity risk | Reduced efficacy | Consider dose reduction |
| Poor (PM) | 0 | Absent/minimal | Highest toxicity risk | No conversion (therapeutic failure) | Alternative drug or major dose change |
CYP2D6: The Most Complex Pharmacogene
Genetic Complexity
CYP2D6 is located on chromosome 22q13.2 with flanking pseudogenes (CYP2D7, CYP2D8). Over 130 defined star alleles exist (CYP2D61 through CYP2D6142+). Structural variation includes whole-gene deletions (5 allele), duplications/multiplications, and hybrid genes (such as CYP2D636-CYP2D7 hybrids). CYP2D6 is not reliably genotyped by standard short-read sequencing and requires specialized assays or long-read sequencing.
High-Impact Clinical Examples
Codeine is a prodrug converted to morphine by CYP2D6; ultrarapid metabolizers produce excessive morphine with risk of respiratory depression (fatalities have been reported in children), while poor metabolizers have no analgesic effect. Tamoxifen is converted to its active metabolite endoxifen by CYP2D6; poor metabolizers may have reduced breast cancer outcomes, and CPIC recommends alternative endocrine therapy for PMs. Atomoxetine plasma levels are significantly higher in poor metabolizers, requiring dose reduction.
CYP2C19: Clopidogrel and Beyond
Key Alleles
CYP2C192 (c.681G>A, splice defect) is the most common loss-of-function allele, with a frequency of approximately 15% in Europeans and 30% in East Asians. CYP2C193 (premature stop codon) is more common in East Asian populations. CYP2C19*17 (promoter variant) increases transcription and contributes to the UM phenotype.
Clinical Applications
Clopidogrel is a prodrug requiring CYP2C19 activation; poor and intermediate metabolizers have increased risk of cardiovascular events due to inadequate platelet inhibition, and guidelines recommend alternative antiplatelet therapy (prasugrel, ticagrelor). For proton pump inhibitors, poor metabolizers have higher drug exposure and better acid suppression, while ultrarapid metabolizers may need higher doses. For voriconazole, poor metabolizers face toxicity risk while ultrarapid metabolizers risk subtherapeutic levels; therapeutic drug monitoring is recommended alongside PGx testing.
CYP2C9 and Warfarin
CYP2C92 and 3 are reduced-function alleles affecting warfarin metabolism. Combined with VKORC1 genotype (the pharmacodynamic target), CYP2C9 variants explain approximately 40% of warfarin dose variability. FDA-approved dosing tables incorporate CYP2C9 and VKORC1 genotype. CYP2C9*8 is an important reduced-function allele in populations of African descent that is often missing from older genotyping panels.
Non-CYP Pharmacogenes of Note
DPYD (dihydropyrimidine dehydrogenase) metabolizes fluoropyrimidines (5-FU, capecitabine); poor metabolizers face risk for severe or fatal toxicity, and preemptive testing is increasingly mandated (EMA). TPMT and NUDT15 metabolize thiopurines (azathioprine, 6-mercaptopurine); poor metabolizers face life-threatening myelosuppression. UGT1A1 Gilbert syndrome allele (*28) is associated with irinotecan toxicity. SLCO1B1 variant rs4149056 T>C confers statin myopathy risk, with the strongest evidence for simvastatin.
CPIC Guidelines and Clinical Implementation
CPIC provides peer-reviewed, evidence-based guidelines for gene-drug pairs, with currently over 25 guidelines covering dozens of gene-drug interactions. Guidelines translate genotype and phenotype into actionable prescribing recommendations and are available at cpicpgx.org with regularly updated clinical decision support resources. PharmGKB serves as the comprehensive knowledgebase linking PGx evidence, variant annotations, and clinical guidelines.
Clinical Pearls
CYP2D6 genotyping is technically challenging due to pseudogenes and structural variants; clinical labs must use validated methods that detect copy number variation and hybrid alleles. The prodrug concept is critical: for prodrugs (codeine, clopidogrel), poor metabolizers lack efficacy while ultrarapid metabolizers face toxicity; for active drugs the pattern is reversed. Population-specific allele frequencies must be considered, as testing panels designed primarily for European populations may miss clinically important alleles in other ancestries. CPIC guidelines are freely available and should be the primary reference for genotype-guided prescribing decisions.
References
- Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and Translational Science. 2020;13(1):116-124.
- Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clinical Pharmacology & Therapeutics. 2013;94(3):317-323.
- Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics. 2011;89(3):464-467.
- Gaedigk A, Ingelman-Sundberg M, Miller NA, et al. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clinical Pharmacology & Therapeutics. 2018;103(3):399-401.